X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES MERCK LTD VENUS REMEDIES/
MERCK LTD
 
P/E (TTM) x -4.4 50.9 - View Chart
P/BV x 0.2 7.7 2.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   MERCK LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
MERCK LTD
Dec-16
VENUS REMEDIES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1261,060 11.9%   
Low Rs61623 9.8%   
Sales per share (Unadj.) Rs301.8632.4 47.7%  
Earnings per share (Unadj.) Rs-24.945.7 -54.4%  
Cash flow per share (Unadj.) Rs2.562.3 4.1%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs293.3388.8 75.4%  
Shares outstanding (eoy) m12.3416.60 74.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 23.3%   
Avg P/E ratio x-3.818.4 -20.4%  
P/CF ratio (eoy) x36.713.5 272.1%  
Price / Book Value ratio x0.32.2 14.7%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m1,15413,969 8.3%   
No. of employees `0000.91.6 58.4%   
Total wages/salary Rs m3931,487 26.4%   
Avg. sales/employee Rs Th4,026.16,631.9 60.7%   
Avg. wages/employee Rs Th425.0939.2 45.3%   
Avg. net profit/employee Rs Th-331.8479.4 -69.2%   
INCOME DATA
Net Sales Rs m3,72410,498 35.5%  
Other income Rs m23242 9.3%   
Total revenues Rs m3,74710,741 34.9%   
Gross profit Rs m3951,135 34.8%  
Depreciation Rs m338276 122.8%   
Interest Rs m3540-   
Profit before tax Rs m-2751,102 -25.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32343 9.2%   
Profit after tax Rs m-307759 -40.4%  
Gross profit margin %10.610.8 98.0%  
Effective tax rate %-11.531.1 -36.9%   
Net profit margin %-8.27.2 -114.0%  
BALANCE SHEET DATA
Current assets Rs m2,6386,410 41.2%   
Current liabilities Rs m2,3058,828 26.1%   
Net working cap to sales %8.9-23.0 -38.8%  
Current ratio x1.10.7 157.6%  
Inventory Days Days13558 234.8%  
Debtors Days Days4638 120.7%  
Net fixed assets Rs m4,8711,406 346.3%   
Share capital Rs m123166 74.3%   
"Free" reserves Rs m3,4966,286 55.6%   
Net worth Rs m3,6196,455 56.1%   
Long term debt Rs m1,3740-   
Total assets Rs m7,5098,828 85.1%  
Interest coverage x0.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.2 41.7%   
Return on assets %0.68.6 7.3%  
Return on equity %-8.511.8 -72.1%  
Return on capital %1.617.1 9.3%  
Exports to sales %08.3 0.0%   
Imports to sales %13.921.0 65.9%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs m5172,209 23.4%   
Fx inflow Rs m0959 0.0%   
Fx outflow Rs m5172,612 19.8%   
Net fx Rs m-517-1,653 31.2%   
CASH FLOW
From Operations Rs m5141,070 48.1%  
From Investments Rs m-123-750 16.4%  
From Financial Activity Rs m-387-150 258.4%  
Net Cashflow Rs m4171 2.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.2 18.2 1.0%  
FIIs % 0.6 1.0 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 29.1 228.2%  
Shareholders   20,121 28,591 70.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS